-
The Food and Drug Administration (FDA) is proposing a labeling change for over-the-counter vaginal contraceptives containing N-9. The new labeling, when approved, will help users understand that the use of such products can increase vaginal irritation, which actually may heighten the possibility of acquiring the AIDS virus and other STDs from infected partners.
-
Whats the current consensus when it comes to chlamydia screening for adolescents? Take a look at national public health guidelines to help direct you in your practice.
-
Mounting federal deficits coupled with an administration that favors abstinence promotion over contraception means that funding for the Title X family planning program is likely to remain stagnant in the coming years. President Bush sought no additional funding for the program during his first two years in office, and funding increases during the late 1990s did little more than keep pace with inflation.
-
What is your practice when it comes to routinely screening teen-age girls for chlamydia? If you arent performing such testing, you are missing a prime opportunity to reduce the most commonly reported sexually transmitted disease (STD) in the United States.
-
What if you could simplify your current protocol for emergency contraception (EC)? Results of a recent international multicenter randomized trial indicate that three effective options exist for emergency contraception.
-
How many of your patients have insurance coverage for contraceptives? Get ready to see more of them, as 20 states have passed legislation requiring health plans to pay for contraceptive products.
-
Promote womens health issues during the annual observance of National Womens Health Week, scheduled this year for May 11-17. Use the following web sites as resources.
-
Editors Note: The following summaries represent a selection of papers from among those presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 27-30, 2002, in San Diego and the 40th annual meeting of the Infectious Disease Society of America (IDSA), held October 24-27, 2002, in Chicago.
-
FluMist Recommended for FDA Approval; Britain Extends Pet Travel to United States; Nipah Confirmed in Bangladesh.
-
The FDA has approved a new anti-tumor necrosis factor alpha (TNF alpha) drug for the treatment of rheumatoid arthritis (RA).
